AVEO Oncology to Present at Upcoming Conferences
Get Alerts AVEO Hot Sheet
Join SI Premium – FREE
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will be presenting at the following investor conferences:
- The 19th Annual Rodman & Renshaw Global Investment Conference on Tuesday, September 12, 2017 at 9:35 a.m. Eastern Time. The conference is being held at the Lotte New York Palace Hotel.
- The Cantor Fitzgerald 2017 Global Healthcare Conference on Wednesday, September 27, 2017 at 4:00 p.m. Eastern Time. The conference is being held at the InterContinental New York Barclay Hotel.
A live webcast of the presentations can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast will be archived for 30 days following the presentation date.
About AVEO
AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The Company is focused on seeking to develop and commercialize its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for renal cell carcinoma and other cancers. AVEO is leveraging multiple partnerships aimed at developing and commercializing tivozanib in oncology indications outside of North America, and at progressing its pipeline of novel therapeutic candidates in cancer and cachexia (wasting syndrome). Tivozanib (FOTIVDA®) is approved by the European Commission for the treatment of adult patients with advanced renal cell carcinoma (RCC) in the European Union plus Norway and Iceland. For more information, please visit the company’s website at www.aveooncology.com.
AVEO Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of AVEO that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Actual results or events could differ materially due to a number of important factors, including risks discussed in the section titled “Risk Factors” in AVEO’s most recent Annual Report on Form 10-K, its quarterly reports on Form 10-Q and its other filings with the SEC. The forward-looking statements in this press release represent AVEO’s views as of the date of this press release. AVEO anticipates that subsequent events and developments may cause its views to change. While AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing AVEO’s views as of any date other than the date of this press release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170905005163/en/
AVEO:
Argot Partners
David Pitts, (212) 600-1902
[email protected]
Source: AVEO Oncology
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apnimed prices IPO at $16 per share, raising $192 million
- Securitize (SECZ) files for 151.6M share offering by selling stockholders.
- East West Ave Acquisition prices $100M IPO on Nasdaq
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Cantor FitzgeraldSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share